Why the study?
What are the pharmacokinetics and pharmacodynamics of a single 50 mg oral dose of captopril in patients undergoing continuous ambulatory peritoneal dialysis?
What are the pharmacokinetics and pharmacodynamics of a single 50 mg oral dose of captopril in patients undergoing continuous ambulatory peritoneal dialysis?
Answers are grounded in this paper and cite their sources.
Captopril is eliminated by continuous ambulatory peritoneal dialysis, and its antihypertensive effects may be prolonged in this patient population.
Pharmacokinetics and pharmacodynamics of captopril were studied in 5 continuous ambulatory peritoneal dialysis (CAPD) patients (including 2 hypertensive patients) after single oral administration of 50 mg captopril. The pharmacokinetic parameters for plasma free unchanged captopril were time to maximal concentration 1.1 +/- 0.3 h, maximal plasma concentration 387 +/- 75 ng X ml-1, elimination half-life 1.0 +/- 0.3 h, and the area under the concentration-time curve 711 +/- 144 ng X h X ml-1. For plasma total captopril (the sum of free unchanged captopril and its disulfide compounds) the values were time to maximal concentration 3.5 +/- 0.6 h and maximal plasma concentration 2,777 +/- 429 ng X ml-1. Captopril was detected in the dialysis fluid in all CAPD patients. Blood pressures in the 2 hypertensive CAPD patients were lower at 24 h after than before captopril administration. These results suggest that captopril may be eliminated by CAPD. In addition, there is a possibility that the antihypertensive effects of captopril may be prolonged in hypertensive CAPD patients.
No takes yet. Share an insight, caveat, or question.
Fujimura et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: